Nonalcoholic fatty liver disease (NAFLD/steatosis) is a metabolic disease characterized by the incorporation of fat into hepatocytes. In this study, we developed an in vitro model for NAFLD based on hepatocyte-like cells (HLCs) differentiated from human pluripotent stem cells. We induced fat storage in these HLCs and detected major expression changes of metabolism-associated genes, as well as an overall reduction of liver-related microRNAs. We observed an upregulation of the lipid droplet coating protein Perilipin 2 (PLIN2), as well as of numerous genes of the peroxisome proliferator-activated receptor (PPAR) pathway, which constitutes a regulatory hub for metabolic processes. Interference with PLIN2 and PPARα resulted in major alterations in gene expression, especially affecting lipid, glucose, and purine metabolism. Our model recapitulates many metabolic changes that are characteristic for NAFLD. It permits the dissection of disease-promoting molecular pathways and allows us to investigate the influences of distinct genetic backgrounds on disease progression.
Get full access to this article
View all access options for this article.
References
1.
CohenJC, HortonJD and HobbsHH. (2011). Human fatty liver disease: old questions and new insights. Science, 332:1519–1523.
2.
PerryRJ, CamporezJP, KursaweR, TitchenellPM, ZhangD, PerryCJ, JurczakMJ, AbudukadierA, HanMS, et al. (2015). Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell, 160:745–758.
3.
BasaranogluM, BasaranogluG and SenturkH. (2013). From fatty liver to fibrosis: a tale of “second hit”. World J Gastroenterol, 19:1158–1165.
4.
OkumuraT. (2011). Role of lipid droplet proteins in liver steatosis. J Physiol Biochem, 67:629–636.
5.
ThieleC and SpandlJ. (2008). Cell biology of lipid droplets. Curr Opin Cell Biol, 20:378–385.
6.
GreenbergAS, ColemanRA, KraemerFB, McManamanJL, ObinMS, PuriV, YanQW, MiyoshiH and MashekDG. (2011). The role of lipid droplets in metabolic disease in rodents and humans. J Clin Invest, 121:2102–2110.
7.
ListenbergerLL, Ostermeyer-FayAG, GoldbergEB, BrownWJ and BrownDA. (2007). Adipocyte differentiation-related protein reduces the lipid droplet association of adipose triglyceride lipase and slows triacylglycerol turnover. J Lipid Res, 48:2751–2761.
8.
SztalrydC, XuG, DorwardH, TanseyJT, ContrerasJA, KimmelAR and LondosC. (2003). Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation. J Cell Biol, 161:1093–1103.
9.
MiyoshiH, SouzaSC, ZhangHH, StrisselKJ, ChristoffoleteMA, KovsanJ, RudichA, KraemerFB, BiancoAC, ObinMS and GreenbergAS. (2006). Perilipin promotes hormone-sensitive lipase-mediated adipocyte lipolysis via phosphorylation-dependent and -independent mechanisms. J Biol Chem, 281:15837–15844.
10.
BrasaemleDL, BarberT, WolinsNE, SerreroG, Blanchette-MackieEJ and LondosC. (1997). Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. J Lipid Res, 38:2249–2263.
11.
Targett-AdamsP, ChambersD, GledhillS, HopeRG, CoyJF, GirodA and McLauchlanJ. (2003). Live cell analysis and targeting of the lipid droplet-binding adipocyte differentiation-related protein. J Biol Chem, 278:15998–16007.
12.
ImamuraM, InoguchiT, IkuyamaS, TaniguchiS, KobayashiK, NakashimaN and NawataH. (2002). ADRP stimulates lipid accumulation and lipid droplet formation in murine fibroblasts. Am J Physiol Endocrinol Metab, 283:E775–E783.
13.
MotomuraW, InoueM, OhtakeT, TakahashiN, NagamineM, TannoS, KohgoY and OkumuraT. (2006). Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. Biochem Biophys Res Commun, 340:1111–1118.
14.
ImaiY, BoyleS, VarelaGM, CaronE, YinX, DhirR, DhirR, GrahamMJ and AhimaRS. (2012). Effects of perilipin 2 antisense oligonucleotide treatment on hepatic lipid metabolism and gene expression. Physiol Genomics, 44:1125–1131.
15.
ImaiY, VarelaGM, JacksonMB, GrahamMJ, CrookeRM and AhimaRS. (2007). Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide. Gastroenterology, 132:1947–1954.
16.
McManamanJL, BalesES, OrlickyDJ, JackmanM, MacLeanPS, CainS, CrunkAE, MansurA, GrahamCE, BowmanTA and GreenbergAS. (2013). Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease. J Lipid Res, 54:1346–1359.
17.
TakahashiY, SoejimaY and FukusatoT. (2012). Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol, 18:2300–2308.
18.
MachadoMV, MichelottiGA, XieG, de AlmeidaTP, BoursierJ, BohnicB, GuyCD and DiehlAM. (2015). Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One, 10:e0127991.
19.
RicchiM, OdoardiMR, CarulliL, AnzivinoC, BallestriS, PinettiA, FantoniLI, MarraF, BertolottiM, et al. (2009). Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol, 24:830–840.
20.
De GottardiA, VinciguerraM, SgroiA, MoukilM, Ravier-Dall'AntoniaF, PazienzaV, PugnaleP, FotiM and HadengueA. (2007). Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab Invest, 87:792–806.
21.
CurrieE, SchulzeA, ZechnerR, WaltherTC and FareseRVJr. (2013). Cellular fatty acid metabolism and cancer. Cell Metab, 18:153–161.
22.
CantorJR and SabatiniDM. (2012). Cancer cell metabolism: one hallmark, many faces. Cancer Discov, 2:881–898.
23.
GodoyP, HewittNJ, AlbrechtU, AndersenME, AnsariN, BhattacharyaS, BodeJG, BolleynJ, BornerC, et al. (2013). Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol, 87:1315–1530.
24.
ThomsonJA, Itskovitz-EldorJ, ShapiroSS, WaknitzMA, SwiergielJJ, MarshallVS and JonesJM. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282:1145–1147.
25.
WangY and AdjayeJ. (2011). A cyclic AMP analog, 8-Br-cAMP, enhances the induction of pluripotency in human fibroblast cells. Stem Cell Rev, 7:331–341.
26.
IwaniukKM, SchiraJ, WeinholdS, JungM, AdjayeJ, MullerHW, WernetP and TrompeterHI. (2011). Network-like impact of MicroRNAs on neuronal lineage differentiation of unrestricted somatic stem cells from human cord blood. Stem Cells Dev, 20:1383–1394.
27.
TrompeterHI, AbbadH, IwaniukKM, HafnerM, RenwickN, TuschlT, SchiraJ, MullerHW and WernetP. (2011). MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One, 6:e16138.
28.
HayDC, ZhaoD, FletcherJ, HewittZA, McLeanD, Urruticoechea-UriguenA, BlackJR, ElcombeC, RossJA, WolfR and CuiW. (2008). Efficient differentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells, 26:894–902.
29.
HayDC, FletcherJ, PayneC, TerraceJD, GallagherRC, SnoeysJ, BlackJR, WojtachaD, SamuelK, et al. (2008). Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. Proc Natl Acad Sci U S A, 105:12301–12306.
30.
JozefczukJ, PrigioneA, ChavezL and AdjayeJ. (2011). Comparative analysis of human embryonic stem cell and induced pluripotent stem cell-derived hepatocyte-like cells reveals current drawbacks and possible strategies for improved differentiation. Stem Cells Dev, 20:1259–1275.
31.
WruckW, KashoferK, RehmanS, DaskalakiA, BergD, GralkaE, JozefczukJ, DrewsK, PandeyV, et al. (2015). Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes. Sci Data, 2:150068.
32.
McMullenPD, BhattacharyaS, WoodsCG, SunB, YarboroughK, RossSM, MillerME, McBrideMT, LeCluyseEL, ClewellRA and AndersenME. (2014). A map of the PPARalpha transcription regulatory network for primary human hepatocytes. Chem Biol Interact, 209:14–24.
33.
Grygiel-GorniakB. (2014). Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications—a review. Nutr J, 13:17.
34.
PawlakM, LefebvreP and StaelsB. (2015). Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol, 62:720–733.
35.
Targett-AdamsP, McElweeMJ, EhrenborgE, GustafssonMC, PalmerCN and McLauchlanJ. (2005). A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein. Biochim Biophys Acta, 1728:95–104.
36.
PawellaLM, HashaniM, EiteneuerE, RennerM, BartenschlagerR, SchirmacherP and StraubBK. (2014). Perilipin discerns chronic from acute hepatocellular steatosis. J Hepatol, 60:633–642.
37.
RogueA, AntherieuS, VluggensA, UmbdenstockT, ClaudeN, de la Moureyre-SpireC, WeaverRJ and GuillouzoA. (2014). PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Toxicol Appl Pharmacol, 276:73–81.
38.
MichalikL, AuwerxJ, BergerJP, ChatterjeeVK, GlassCK, GonzalezFJ, GrimaldiPA, KadowakiT, LazarMA, et al. (2006). International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev, 58:726–741.
39.
FrancqueS, VerrijkenA, CaronS, PrawittJ, PaumelleR, DerudasB, LefebvreP, TaskinenMR, Van HulW, et al. (2015). PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. J Hepatol, 63:164–173.
40.
FogartyS and HardieDG. (2010). Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta, 1804:581–591.
41.
YamadaPM, MehtaHH, HwangD, RoosKP, HevenerAL and LeeKW. (2010). Evidence of a role for insulin-like growth factor binding protein (IGFBP)-3 in metabolic regulation. Endocrinology, 151:5741–5750.
42.
AsbyDJ, CudaF, BeyaertM, HoughtonFD, CagampangFR and TavassoliA. (2015). AMPK activation via modulation of de novo purine biosynthesis with an inhibitor of ATIC homodimerization. Chem Biol, 22:838–848.
43.
PirolaCJ, Fernandez GianottiT, CastanoGO, MallardiP, San MartinoJ, Mora Gonzalez Lopez LedesmaM, FlichmanD, MirshahiF, SanyalAJ and SookoianS. (2015). Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut, 64:800–812.
44.
CermelliS, RuggieriA, MarreroJA, IoannouGN and BerettaL. (2011). Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One, 6:e23937.
45.
HsuSH, WangB, KotaJ, YuJ, CostineanS, KutayH, YuL, BaiS, La PerleK, et al. (2012). Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest, 122:2871–2883.
46.
TsaiWC, HsuSD, HsuCS, LaiTC, ChenSJ, ShenR, HuangY, ChenHC, LeeCH, et al. (2012). MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest, 122:2884–2897.
47.
TanW, LiY, LimSG and TanTM. (2014). miR-106b-25/miR-17–92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol, 20:5962–5972.
48.
JozefczukJ, KashoferK, UmmanniR, HenjesF, RehmanS, GeenenS, WruckW, RegenbrechtC, DaskalakiA, et al. (2012). A systems biology approach to deciphering the etiology of steatosis employing patient-derived dermal fibroblasts and iPS cells. Front Physiol, 3:339.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
